Infections
Conditions
Keywords
High risk aspergillosis infection patients
Brief summary
ADVANCE THERAPY ASPERGILLOSIS INVASIVE BY PCR DETECTION
Detailed description
ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS
Interventions
PROCEDUREAspergillus PCR technique
Aspergillus DNA PCR technique
PROCEDUREAspergillus AGA technique
Aspergillus AGA technique
Sponsors
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signature of informed consent to participate in the study. * Adult patients (\> 18 years), diagnosed with acute myelogenous leukemia or myelodysplastic syndrome with chemotherapy (CT) intensive, or admitted to undergo allogeneic hematopoietic progenitor cells, or transplantation with graft versus host disease. * The patient should be included in this protocol from the start of their chemotherapy or conditioning therapy as reflected in another section.
Exclusion criteria
* Employment of antifungal prophylaxis (30 days prior to inclusion) with triazole / polyene with activity against Aspergillus (itraconazole, voriconazole, posaconazole, amphotericin B inhalation). * Use of other systemic antifungal activity against Aspergillus (amphotericin, terbinafine, flucytosine, echinocandins, etc.). Therefore it will Fluconazole prophylaxis exclusively. * Background of IFI proven / probable prior * Probable IFI / tested at the time of inclusion in the study. * Exclusion will cause a lack of compliance with the inclusion criteria. * Patients who have a lack of follow biweekly with galactomannan or PCR. Have a bacterial infection not properly treated and controlled before starting empirical antifungal treatment (according to the definition given above). And finally they have a neutropenia of short duration that it creates a significant risk of IFI. This information will not be known logically to include the patient in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of PCR technique for detection of Aspergillus DNA versus the standard technique for the determination of galactomannan Antigen (AGA) in serum | 18-20 months | To value the percentage of patients with likely/proven invasive fungal infection, diagnosed using only AGA tecnique or using AGA and PCR tecniques together. |
Countries
Spain
Outcome results
None listed